TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01592422

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous cytokine-induced killer cell
Description: Subjects receive autologous cytokine-induced killer cell infusion every month in the absence of disease progression or unacceptable toxicity.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Supportive Care
Description: Best Supportive Care in the absence of disease progression
Study: NCT03050372

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: LFMS - Active
Description: A non-invasive form of brain stimulation administered from a device resembling a bird cage. The device covers the top part of the head for the duration of stimulation (in the current study, 20 minutes)

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: LFMS - Sham
Description: A simulation of the LFMS-Active intervention, using the same device that produces a sound similar to the sound made by the device during the active treatment, for a similar duration (in the current study, 20 minutes)
Study: NCT00972036

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SIR-spheres® (Selective Internal Radiation Therapy)
Description: SIR-spheres® will be administered at 70%, 85% and 100% of the calculated individual patient dose (approximately 1 month prior to SIR-spheres® administration).The first cohort will receive SIRSpheres® at 70% of the individually calculated patient dose, the second will receive 85% of the calculated patient dose, and the third will receive 100% of the calculated patient dose.
Study: NCT01435499

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma GVAX
Description: Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma GVAX
Description: Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: melanoma GVAX
Description: Melanoma GVAX is given as intradermal injections every 28 days x 4 doses. Cohort A will receive 5E7 cells/dose; cohorts B and C will receive 2E8 cells/dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 200mg/m2 given as a single dose, intravenously, one day prior to each of the 4 vaccinations to patients in cohort C only
Study: NCT03096496

Intervention type: OTHER
Intervention: QoL questionnaires
Description: Quality of life questionnaires
Study: NCT01532102

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AP611074

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo gel manufactured to appear identical to AP611074 5% gel
Study: NCT04403178

Intervention type: DIAGNOSTIC_TEST
Intervention: Radiographic examination with a Migration of > 40 %
Description: Radiographic examination
Study: NCT04712500

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: AND017 oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AND017
Description: AND017 oral capsule
Study: NCT00839306

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole ER
Description: 50 mg capsule, taken orally, once daily for 26 weeks.
Study: NCT02053766

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (Precedex) infusion starting at 1mcg/ kg/ hr will be administered to study subjects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: Propofol up to 50 mcg/ kg/min will be administered to study subjects.
Study: NCT00839306

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ranitidine
Description: 150 mg capsule, taken orally, twice daily for 26 weeks.
Study: NCT01574365

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTA 402
Study: NCT04181476

Intervention type: DRUG
Group type: OTHER
Intervention: Sunscreening Agents
Description: Four different sunscreens
Study: NCT03942471

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Mindfulness Based Stress Reduction
Description: Mindfulness-Based Stress Reduction (MBSR) is a well-defined and systematic patient-centered educational approach which provides training in mindfulness meditation to teach adolescents with Type 1 diabetes to take better care of themselves and live healthier and more adaptive lives by learning to become more connected to the present moment through the use of breath and training for awareness of the moment.
Study: NCT00365157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin Mesylate
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study: NCT03458481

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SOF
Description: 400 mg tablet administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG181
Description: Capsule administered orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAG181
Description: Capsule administered orally once daily
Study: NCT02891018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel controlled release balloon catheter Vasoguard TM

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: paclitaxel release coronary balloon catheter SeQuent Please
Study: NCT02080143

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal Adhesion Patch
Study: NCT01164579

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tasocitinib plus Methotrexate
Description: Tofacitinib (CP 690,550) 10 mg BID, tablets + methotrexate (MTX) 10 mg/wk to 20 mg/wk, titrated over 2 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofacitinib plus placebo methotrexate
Description: Tofacitinib (CP-90,550) 10 mg BID, tablets. Placebo to match methotrexate (MTX) capsules titrated as in Treatment Arm 1.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tofacitinib plus Methotrexate
Description: Methotrexate (MTX) 10 mg/wk to 20 mg/wk, capsules, titrated over 2 months. Placebo in tablets to match tofacitinib
Study: NCT02080143

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Thermal Adhesion Patch
Study: NCT01785329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: alirocumab SAR236553 (REGN727)
Description: Pharmaceutical form:Solution for injection Route of administration: Subcutaneous
Study: NCT02871453

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Scalp Acupuncture Treatment
Description: The Motor Area of the scalp acupuncture is located over the anterior central convolution of the cerebral cortex, being a line starting from a point 0.5cm posterior to the midpoint of the anterior-posterior midline of the head and stretching diagonally to the juncture between the eyebrow-occipital line and the anterior border of the corner of temporal hairline is indistinct, draw a vertical line upward from the middle point of the zygomatic arch to the eyebrow-occipital line, the intersection of the two lines is the projection of the Motor Area. Needles will be inserted in an about 15 degree angle to a depth of 1.0-1.5cm. Needles are rotated at least 200 revolutions per minute for 1 minute every 10 minutes for a total of 60 minutes. five times a week, 8 weeks in total.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation treatment
Description: The rehabilitation program was designed according to the Chinese stroke rehabilitation treatment guidelines, which included physical therapy (PT) and occupational therapy (OT). The rehabilitation programs will be carried out five times a week (that is, Monday to Friday) for 8 weeks, and every time the rehabilitation treatment( PT and OT) will last approximately for 1 hour. All rehabilitation treatment will be carried out by qualified therapists.
Study: NCT01257386

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asacol®
Description: 400mg tablets

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mesalazine
Description: 400mg tablets
Study: NCT00692523

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Recreational therapy activities
Description: Recreational therapy sessions will include leisure activities such as playing cards and/or doing arts and crafts.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nintendo Wii
Description: The Nintendo Wii gaming system, released in 2005, introduced a new style of virtual reality by using a wireless controller that interacts with the player through a motion detection system. Nintendo Wii involves the incorporation of 3-dimensional accelerometer technology that can respond to changes in direction, speed, and acceleration, down to the most delicate movements. Specifically, the controllers use embedded acceleration sensors to enable players' wrist, arm, and hand movements to interact with the games. Tilt measurements allow users to move characters, while the accurate three-axis acceleration sensing easily transforms the controller into a virtual sword, gearshift, or musical instrument
Study: NCT03378895

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: online questionnaire
Description: Risk assessment identified by online questionnaire
Study: NCT01956526

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CORolla™ TAA device
Study: NCT01234675

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milnacipran
Description: 50 mg twice daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 mg twice daily
Study: NCT00857311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag vaccine (V520)
Description: 3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^9 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Comparator: Placebo
Description: 1.0 mL intramuscular injection of Placebo at Day 1 and Weeks 4 and 26

Intervention type: BIOLOGICAL
Group type: SHAM_COMPARATOR
Intervention: Comparator: Open Label Tetanus and Diptheria Toxoids Adsorbed
Description: 0.5 mL Open Label Tetanus and Diptheria Toxoids Adsorbed (Td) intramuscular injection at Day 1 only

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MRKAd5 HIV-1 gag vaccine (V520)
Description: 3-dose prime boosting regimen of 1.0-mL intramuscular injections of 1x10\^10 viral particles/dose of MRKAd5 HIV-1 gag vaccine (V520) at Day 1 and Weeks 4 and 26
Study: NCT02232919

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation
Description: If subjects qualify with respect to protocol requirements, the Medtronic Activa system will be implanted with the leads placed bilaterally in the VMH.~Adjustment of DBS parameters at the three months visit will be performed to improve efficacy when the goal of 3% body weight loss mark was not achieved during this period of continuous stimulation. Subjects will be seen monthly after discharge throughout the study period. At visits, safety will be assessed through blood/urine tests, blood pressure measurements, verbal interviews with the subjects and family, quarterly formal psychiatric tests as well as QOL scales.~The determination of efficacy will be the within-group percent change in weight at the end of the DBS treatment period compared to baseline.
Study: NCT02936297

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: High dose Gluten

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low dose Gluten

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Lactose free placebo
Study: NCT02767024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium nitroprusside
Description: Sodium nitroprusside is a medication used to lower blood pressure.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dobutamine
Description: Dobutamine is a direct-acting inotropic agent whose primary activity results from stimulation of the ÃŸ receptors of the heart while producing comparatively mild chronotropic, hypertensive, arrhythmogenic, and vasodilative effects.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Furosemide
Description: Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
Study: NCT00933569

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LACTIC ACID(ND)
Description: treatment period: 21 consecutive days
Study: NCT00525642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
Description: Docetaxel 75mg/m2, doxorubicin 50mg/m2 or epirubicin 60mg/m2, cyclophosphamide 500mg/m2 six cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel, Doxorubicin or Epirubicin, Cyclophosphamide
Description: Docetaxel 100mg/m2 four cycles; Doxorubicin 60mg/m2 or epirubicin 75mg/m2 ,cyclophosphamide 600mg/m2) four cycles
Study: NCT02674295

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 50 mg
Description: 50 mg of oral esketamine, fortified with a microtracer dose of 14C-esketamine, as an aqueous solution mixed with apple juice for administration (80 mL total volume)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esketamine 20 mg
Description: 20 mg of intravenous esketamine in 30 mL, fortified with a microtracer dose of 14C-esketamine, as a 30-minute intravenous infusion.
Study: NCT02939859

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Microcannula Harvest Adipose
Description: Use of Closed Syringe Microcannula Harvest Autologous Adipose-Derived Stem/Stromal Cells

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Centricyte 1000
Description: Use of Centricyte 1000 closed system digestion adipose tissue stromal vascular fraction to create a AD-cSVF

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sterile Normal Saline IV deployment AD-cSVF
Description: Sterile Normal Saline Suspension AD-cSVF in 500 cc IV use
Study: NCT00307671

Intervention type: DRUG
Group type: OTHER
Intervention: prednisone, methylprednisolone,cyclophosphamides
Description: treatment conventional

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, Azathioprine,prednisone,methylprednisolone
Description: reduction dose

Intervention type: DRUG
Group type: OTHER
Intervention: Mycophenolate mofetil,methotrexate
Description: in the treatment conventional and in the reduction dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil,methotrexate
Description: in the treatment conventional and in the reduction dose
Study: NCT02035488

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tobramycin
Description: Tobramycin dry powder 30 mg inhalation per dose; Dose escalation: 30-60-120 and 240 mg, each one time. One dose per week.
Study: NCT03015961

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EXPAREL and bupivacaine HCl
Description: Drug: EXPAREL EXPAREL and bupivacaine HCl~Other Name: bupivacaine liposome injectable suspension Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupivacaine HCl
Description: Drug: Bupivacaine Single dose of bupivacaine HCl 0.5%~Other Name: bupivacaine HCl
Study: NCT05324527

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hand Massage
Description: Hand massage procedure, 8 minutes to both hands and a total of 16 minutes hand massage was applied with liquid petrolatum.
Study: NCT03881267

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Human Autologous Homologous Skin Construct
Description: Application of a autologous human derived skin polar units

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Additional Outer Dressing Application
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional Outer Dressing Application
Description: Application of Moisture retentive dressing, and a multi-layer compression dressing

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fibracol Wound Dressing
Description: Application of Collagen Alginate Dressing
Study: NCT03807271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Calculated and graphically produced depth of anesthesia (Smart Pilot® View)
Description: Smart Pilot® View is a device integrated in the ventilator used under general anesthesia. The depth of anesthesia is calculated based on age, weight, height and the medication given - both volatiles and intravenous. The device does not control the supply of medication directly, but provides an estimate of anesthesia depth that can help the anesthesia team to control the supply of anesthetic agents under general anesthesia, ie indirectly.
Study: NCT04304898

Intervention type: OTHER
Intervention: Home spirometry
Description: * Patients will perform daily home spirometry for three months with a Bluetooth-enabled validated, CE-marked home spirometer (Spiro bank Smart, MIR, Italy). Subsequently, patients will perform weekly home spirometry for two years in total. During this period, patients will be asked to perform three measurements each week on the same day.~* Hospital-based spirometry will be performed according to international guidelines.~* Patients will complete patient-reported outcomes (PROMs) online in the secured application every six months.
Study: NCT02767024

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Furosemide
Description: Furosemide is a prescription drug used to treat hypertension (high blood pressure) and edema. Learn about side effects, warnings, dosage, and more.
Study: NCT01954056

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydrocortisone
Description: • 7 day course of hydrocortisone (hydrocortisone sodium succinate, plain; will not have benzyl alcohol) given through intravenous line or by intramuscular injection if no intravenous line).~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 7 days of intravenous or intramuscular placebo (normal saline in equal volume)~1 mg/kg loading dose x 1; 0.5 mg/kg q 6 hours x 12 doses; 0.5 mg/kg q 12 hours x 4 doses; 0.5 mg/kg q day x 1 dose
Study: NCT04562129

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interleukin-2
Description: High dose interleukin-2 (HD IL2) administered week 1 and 4 of each course (approximately 12 weeks)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Low dose Ipilimumab given at time of HD IL2 administration on day 1 of the first 2 cycles of each course.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be given at a dose of 480 mg IV week 7 of each course.
Study: NCT04323618

Intervention type: DEVICE
Group type: OTHER
Intervention: Breathe Well
Study: NCT03319277

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Decreased opiate prescription
Description: The experimental group will receive 5 tablets of oxycodone 5mg at time of discharge with a paper backup prescription for an additional 10 tablets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Routine opiate prescription
Description: The comparator group will receive 28 tablets of oxycodone 5mg at time of discharge.
Study: NCT03870932

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Motor Imagery physical therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical therapy
Study: NCT01691560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5% calcium sodium phosphosilicate/ sodium monofluorophosphate dentifrice
Description: Dentifrice containing 5.0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 0% calcium sodium phosphosilicate/sodium monofluorophosphate dentifrice
Description: Dentifrice containing 0% w/w calcium sodium phosphosilicate and 1500ppmF as sodium monofluorophosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium monofluorophosphate dentifrice
Description: Dentifrice containing 1000 ppmF as sodium monofluorophosphate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride dentifrice
Description: Dentifrice containing 1100 ppmF as sodium fluoride
Study: NCT06236789

Intervention type: DRUG
Intervention: Ifosfamide/mesna
Description: Ifosfamide 2,500 mg/m2/day for 3 days every 3 weeks with mesna until disease progression
Study: NCT02230904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine (Test product PR 2.3.1)
Description: * Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine (Test product PR 2.3.1)
Description: * Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine (Reference product PR 2.1.1)
Description: * Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal
Study: NCT01093729

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HM11260C
Description: HM11260C 0.5mcg/kg or Placebo
Study: NCT02230904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine (Reference product PR 2.1.1)
Description: * Pharmaceutical form: Transdermal patch~* Concentration: 8 mg/24 hours~* Route of administration: Transdermal